摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,4R,5R)-4-acetoxy-5-(5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl)tetrahydrofuran-2-yl-methyl acetate | 892498-63-4

中文名称
——
中文别名
——
英文名称
(2S,4R,5R)-4-acetoxy-5-(5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl)tetrahydrofuran-2-yl-methyl acetate
英文别名
5-amino-3-(2',5'-di-O-acetyl-3'-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one;[(2S,4R,5R)-4-acetyloxy-5-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)oxolan-2-yl]methyl acetate
(2S,4R,5R)-4-acetoxy-5-(5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl)tetrahydrofuran-2-yl-methyl acetate化学式
CAS
892498-63-4
化学式
C14H16N4O6S
mdl
——
分子量
368.37
InChiKey
OJGMMGYQCZBVLU-YGOYTEALSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    607.5±65.0 °C(Predicted)
  • 密度:
    1.55±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    25
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    159
  • 氢给体数:
    1
  • 氢受体数:
    10

反应信息

  • 作为反应物:
    描述:
    (2S,4R,5R)-4-acetoxy-5-(5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl)tetrahydrofuran-2-yl-methyl acetate 在 lipozyme 435 作用下, 以 乙醇甲苯乙腈 为溶剂, 反应 36.0h, 生成 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyltetrahydrofuran-3-yl acetate glutaric acid
    参考文献:
    名称:
    CO-CRYSTALS OF 5-AMINO-2-OXOTHIAZOLO[4,5-D]PYRIMIDIN-3(2H)-YL-5-HYDROXYMETHYL TETRAHYDROFURAN-3-YL ACETATE AND METHODS FOR PREPARING AND USING THE SAME
    摘要:
    Formula I化合物的共晶体及其药物组合物是治疗疾病的新型治疗药物,例如人类免疫缺陷病毒(HIV)感染、乙型肝炎病毒(HBV)感染、丙型肝炎病毒(HCV)感染和癌症。这些共晶体比Formula I化合物对应的对甲苯磺酸盐形式更稳定,对氧化和水解更稳定,具有更好的药代动力学特性和优越的生物活性。
    公开号:
    US20160176899A1
  • 作为产物:
    参考文献:
    名称:
    CO-CRYSTALS OF 5-AMINO-2-OXOTHIAZOLO[4,5-D]PYRIMIDIN-3(2H)-YL-5-HYDROXYMETHYL TETRAHYDROFURAN-3-YL ACETATE AND METHODS FOR PREPARING AND USING THE SAME
    摘要:
    Formula I化合物的共晶体及其药物组合物是治疗疾病的新型治疗药物,例如人类免疫缺陷病毒(HIV)感染、乙型肝炎病毒(HBV)感染、丙型肝炎病毒(HCV)感染和癌症。这些共晶体比Formula I化合物对应的对甲苯磺酸盐形式更稳定,对氧化和水解更稳定,具有更好的药代动力学特性和优越的生物活性。
    公开号:
    US20160176899A1
点击查看最新优质反应信息

文献信息

  • Prodrugs of 5-amino-3-(3'-deoxy-b-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
    申请人:Haley J. Gregory
    公开号:US20080032999A1
    公开(公告)日:2008-02-07
    The invention is directed to 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione prodrugs, whose metabolized parent compound has immunomodulatory activity. The invention also relates to the therapeutic use of such prodrugs and pharmaceutical compositions thereof in treating disease states associated with abnormal cell growth, such as cancer.
    这项发明涉及5-基-3-(3'-去氧-β-D-核糖呋喃苷基)-噻唑并[4,5-d]嘧啶-2,7-二酮前药,其代谢后的母化合物具有免疫调节活性。该发明还涉及使用这种前药及其制剂治疗与异常细胞生长相关的疾病状态,如癌症。
  • 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
    申请人:Webber Stephen E.
    公开号:US20110275589A1
    公开(公告)日:2011-11-10
    The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds and prodrugs.
    本发明涉及具有免疫调节活性的3,5-二取代和3,5,7-三取代-3H-噁唑并[4,5-d]嘧啶-2-酮化合物及其前药。本发明还涉及使用此类化合物及其前药的治疗或预防用途,以及含有它们的制药组合物和通过给予这些化合物和前药的有效量来治疗本文所述疾病和疾病的方法。
  • 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
    申请人:Webber Stephen E.
    公开号:US20120121541A1
    公开(公告)日:2012-05-17
    The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds and prodrugs.
    本发明涉及具有免疫调节活性的3,5-二取代和3,5,7-三取代-3H-噁唑和3H-噻唑[4,5-d]嘧啶-2-酮化合物及其前药。本发明还涉及使用这些化合物和前药的治疗或预防用途,以及含有它们的制药组合物,并通过给予这些化合物和前药的有效剂量来治疗本文所述的疾病和障碍的方法。
  • 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof
    申请人:Webber Stephen E.
    公开号:US20130259831A1
    公开(公告)日:2013-10-03
    The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds and prodrugs.
    该发明涉及具有免疫调节活性的3,5-二取代和3,5,7-三取代-3H-噁唑并[4,5-d]嘧啶-2-酮化合物及其前药。该发明还涉及使用这些化合物的治疗或预防用途,以及含有它们的制药组合物,以及通过给予这些化合物和前药的有效量来治疗本文所述的疾病和障碍的方法。
  • P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]pyrimidine-2-one and Methods for Preparation
    申请人:Kucera David
    公开号:US20090197826A1
    公开(公告)日:2009-08-06
    The present disclosure relates to p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and to its use in treating conditions such as viral infections, tumors, and cancer. Also disclosed is a method of preparing the p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and methods for producing furanose compounds which are useful intermediates in the preparation of pharmaceutical compounds such as p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and the like.
    本公开涉及5-基-3-(2'-O-乙酰-3'-脱氧-β-D-核糖呋喃苷基)-3H-噻唑并[4,5-d]嘧啶-2-酮的对甲苯磺酸盐及其在治疗病毒感染、肿瘤和癌症等疾病中的应用。还公开了制备5-基-3-(2'-O-乙酰-3'-脱氧-β-D-核糖呋喃苷基)-3H-噻唑并[4,5-d]嘧啶-2-酮的对甲苯磺酸盐的方法,以及用于制备药物化合物(如对甲苯磺酸盐的5-基-3-(2'-O-乙酰-3'-脱氧-β-D-核糖呋喃苷基)-3H-噻唑并[4,5-d]嘧啶-2-酮等)的有用中间体呋喃糖化合物的方法。
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)